Pharma Services

• Intimation of an analyst meet scheduled from May 27 to 29, 2026, pursuant to SEBI LODR Regulation 30. • Company reported FY26 revenue of INR 35,105M with 19.4% adj. EBITDA margin and a 29.4% revenue